文献速递核素与放射性配体治疗肿瘤 PET/CT

[177Lu]Lu-PSMA-617作为转移性去势抵抗性前列腺癌一线全身治疗:一项真实世界研究

[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-03-12

本研究回顾本中心2015至2023年连续40例接受[177Lu]Lu-PSMA-617一线治疗的转移性去势抵抗性前列腺癌患者,中位年龄68.5岁,中位PSA 41 ng/mL。最佳PSA缓解率(≥50%下降)为62.5%(25/40),客观影像缓解率34.2%(13/38)。中位随访36个月,中位影像学无进展生存期12个月(95%CI 9-15),中位总生存期17个月(95%CI 12-22)。结论提示其作为一线治疗安全有效,但需进一步试验确立其一线地位。

要点

  • 40例初治mCRPC患者接受[177Lu]Lu-PSMA-617一线治疗,最佳PSA缓解率(≥50%下降)为62.5%(25/40)。
  • 38例可评估影像学缓解,部分缓解13例,客观影像缓解率34.2%。
  • 中位rPFS 12个月(95%CI 9-15),中位OS 17个月(95%CI 12-22),≥3级贫血4/40(10%)。

核心结论

  • 研究结果提示[177Lu]Lu-PSMA-617作为mCRPC一线治疗是安全有效的选择。
  • 需要进一步试验来明确其作为该情形下 upfront 治疗模式的地位。

研究设计与样本

  • 本研究为真实世界研究,收集并分析本中心2015至2023年连续接受[177Lu]Lu-PSMA-617一线治疗的mCRPC患者数据。
  • 共纳入40例经[68Ga]Ga-PSMA-11 PET/CT证实PSMA阳性的初治mCRPC患者,中位年龄68.5岁(范围45-78),中位PSA 41 ng/mL(范围1-3028)。
  • 患者接受中位累积活度22.2 GBq(范围5.55-44.4)的[177Lu]Lu-PSMA-617,共1-6个周期,间隔8-12周。

主要发现

  • 最佳PSA缓解率(PSA较基线下降≥50%的患者比例)为62.5%(25/40)。
  • 38例可评估影像学缓解,其中13例达部分缓解,客观影像缓解率34.2%。
  • 中位随访36个月,中位影像学无进展生存期12个月(95%CI 9-15),中位总生存期17个月(95%CI 12-22)。
  • 治疗中出现≥3级贫血4/40(10%)、白细胞减少1/40(2.5%)、血小板减少3/40(7.5%)。

关键数值与推荐

  • PSA缓解定义为PSA较基线下降≥50%。
  • 客观影像缓解率定义为达到完全或部分影像学缓解的患者比例。
  • 影像学无进展生存期从治疗开始计算至影像学进展或任何原因死亡。
  • 总生存期从治疗开始计算至任何原因死亡。

临床怎么用

  • 作者认为[177Lu]Lu-PSMA-617作为mCRPC一线治疗是安全有效的选择。
  • 作者指出需要进一步试验来明确其作为该情形下 upfront 治疗模式的地位。

局限性

  • 原文结论指出需要进一步试验来明确[177Lu]Lu-PSMA-617作为该情形下 upfront 治疗模式的地位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The use of [177Lu]Lu-PSMA-617 radioligand therapy has become increasingly recognized as a viable therapeutic approach for patients in the advanced stages of metastatic castration-resistant prostate cancer (mCRPC). However, there is limited data regarding its effectiveness and safety in earlier lines. This study aims to present our institution's experience with [177Lu]Lu-PSMA-617 as a first-line systemic therapy for mCRPC. METHODS: We collected and analyzed data from consecutive mCRPC patients who underwent first-line treatment with [177Lu]Lu-PSMA-617 at our center from 2015 to 2023. The various outcome measures included best prostate-specific antigen-response rate (PSA-RR) (proportion of patients achieving a ≥ 50% decline in PSA); objective radiographic response rate (ORR) (proportion of patients achieving complete or partial radiographic responses); radiographic progression-free survival (rPFS) (measured from treatment initiation until radiographic progression or death from any cause); overall survival (OS) (measured from treatment initiation until death from any cause); and adverse events. RESULTS: Forty treatment-naïve mCRPC patients with PSMA-positive disease on [68Ga]Ga-PSMA-11 PET/CT were included (median age: 68.5 years, range: 45-78; median PSA: 41 ng/mL, range: 1-3028). These patients received a median cumulative activity of 22.2 GBq (range: 5.55-44.4) [177Lu]Lu-PSMA-617 over 1-6 cycles at 8-12 week intervals. A ≥ 50% decline in PSA was observed in 25/40 (62.5%) patients (best PSA-RR). Radiographic responses were evaluated for thirty-eight patients, with thirteen showing partial responses (ORR 34.2%). Over a median follow-up of 36 months, the median rPFS was 12 months (95% confidence interval, CI: 9-15), and the median OS was 17 months (95% CI: 12-22). Treatment-emergent grade ≥ 3 anemia, leucopenia, and thrombocytopenia were noted in 4/40 (10%), 1/40 (2.5%), and 3/40 (7.5%) patients, respectively. CONCLUSION: The findings suggest that [177Lu]Lu-PSMA-617 is a safe and effective option as a first-line treatment in mCRPC. Further trials are needed to definitively establish its role as an upfront treatment modality in this setting.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Satapathy S, Yadav MP, Ballal S, et al. [177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study. Eur J Nucl Med Mol Imaging. 2024. PMID: 38467922. doi:10.1007/s00259-024-06677-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。